AriBio/Arcera Alzheimer's Drug
Alzheimer's Disease
InvestigationalActive
Key Facts
About Acino
Acino is a commercial-stage pharmaceutical company with a dual business model: marketing branded and generic medicines in targeted emerging markets and providing contract manufacturing services for complex oral solid dose formulations. The company is part of Arcera, a global life sciences platform backed by Abu Dhabi's ADQ, providing strategic and financial support. With over 50 years of manufacturing experience, a commercial footprint across four continents, and a focus on advanced drug delivery, Acino positions itself as a reliable partner for expanding access to quality medicines in high-growth regions.
View full company profileOther Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |